Skip to main content
Caplight Logo









Trekka Therapeutics, Inc.

Trekka Therapeutics, Inc.

Private
Saint Paul, MinnesotaHealthcare & Life Scienceshttps://trekkatherapeutics.com/

Last Round

Series A

Feb 5, 2024

Total Funding Raised

$548,000

Company Overview

Trekka Therapeutics, Inc. is a biotechnology company that develops proprietary polymeric drug delivery platforms, CAPRO™ and MORE™, to improve the formulation, solubility, and delivery of small molecule drugs and biologics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Revenue Share

AI Layer

Non-AI

Keywords

drug deliverydrug reformulation505(b)(2)biomaterialsexcipientcontrolled releasetransmucosal deliverydrug delivery platformpharmaceutical licensingbioavailability enhancementdrug delivery techformulation scienceAPIdrug life cycle management

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trekka Therapeutics, Inc. Comparables

Compare Trekka Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Trekka Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Consegna Pharma Inc.
81%
CURE Pharmaceutical
77%
Nualtis
77%

Trekka Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 5, 2024

Trekka Therapeutics, Inc. Investors

Notable investors and investment history

Trekka Therapeutics, Inc. investors
InvestorRounds
NIH RADxGrant

Trekka Therapeutics, Inc. Filings

Explore SEC and related filing metadata, where available.

Trekka Therapeutics, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Trekka Therapeutics, Inc.'s valuation, stock price, and market status.

Is Trekka Therapeutics, Inc. a public or private company?

Trekka Therapeutics, Inc. is a private company.

What is the current stock price of Trekka Therapeutics, Inc.?

Trekka Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Trekka Therapeutics, Inc. worth (valuation)?

Valuation information for Trekka Therapeutics, Inc. is not publicly available.

Can I buy Trekka Therapeutics, Inc. stock?

Trekka Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Trekka Therapeutics, Inc.'s last funding round?

Trekka Therapeutics, Inc.'s most recent funding round was Series A on February 5, 2024.

Who are the main investors in Trekka Therapeutics, Inc.?

Key investors in Trekka Therapeutics, Inc. include NIH RADx.

Will Trekka Therapeutics, Inc. IPO soon?

No public IPO plans have been announced for Trekka Therapeutics, Inc..

How can I track Trekka Therapeutics, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Trekka Therapeutics, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSaint Paul, Minnesota
Employee Range1
Year Founded2018
Last FundingFeb 5, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?